𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Superparamagnetic iron oxide MION as a contrast agent for sodium MRI in myocardial infarction

✍ Scribed by Chris D. Constantinides; J. Rogers; D.A. Herzka; F.E. Boada; D. Bolar; D. Kraitchman; J. Gillen; P.A. Bottomley

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
166 KB
Volume
46
Category
Article
ISSN
0740-3194

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

An intravascular iron‐based contrast agent was used as a sodium (^23^Na) MRI T~2~ relaxant in an effort to suppress the blood signal from the ventricular cavities in normal and infarcted canine myocardium in vivo. ^23^Na MRI signal decreases in blood were attributed to decreases in the fast (T~2f~) and slow (T~2s~) transverse relaxation components, which were quantified as a function of dose and MRI echo time (TE). In vivo ^23^Na MRI signal decreases up to 65% were noted in ventricular blood when imaging under dose and TE conditions of 10 mg/kg body weight and 5 ms, respectively. Contrast injection followed by subsequent ^23^Na MRI in canine myocardial infarction led to a clear delineation of the location of the injured tissue, as identified by postmortem triphenyltetrazolium chloride staining, and to an improvement in the contrast‐to‐noise ratio between the blood in the ventricular chamber and the infarcted tissue that was as high as 3.3‐fold in the postcontrast images in comparison to the precontrast images. Magn Reson Med 46:1164–1168, 2001. © 2001 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

MRI in focal liver disease: A comparison
MRI in focal liver disease: A comparison of small and ultra-small superparamagnetic iron oxide as hepatic contrast agents
✍ Patricia J. Mergo; John D. Engelken; T. Helmberger; Pablo R. Ros 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 824 KB

The purpose of this study was to compare small and ultrasmall superparamagnetic iron oxide particles (SPIO and USPIO, respectively) as MR contrast agents for the evaluation of focal hepatic disease. In two different patient groups (SPIO [n = 53], USPIO [n = 27]), with focal liver disease (metastases

Evaluation of a new ultrasmall superpara
Evaluation of a new ultrasmall superparamagnetic iron oxide contrast agent Clariscan®, (NC100150) for MRI of renal perfusion: Experimental study in an animal model
✍ Rainald Bachmann; Rudolf Conrad; Burkhard Kreft; Oliver Luzar; Wolfgang Block; S 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 544 KB

## Abstract ## Purpose To determine the diagnostic value of a new ultrasmall superparamagnetic iron oxide Clariscan®, (NC100150) for the evaluation of renal perfusion in an animal model using a 3D‐FFE‐EPI sequence. ## Materials and Methods Four groups of four rabbits each were imaged after bolus

Serial in vivo positive contrast MRI of
Serial in vivo positive contrast MRI of iron oxide-labeled embryonic stem cell-derived cardiac precursor cells in a mouse model of myocardial infarction
✍ Venkatesh Mani; Eric Adler; Karen C. Briley-Saebo; Anne Bystrup; Valentin Fuster 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 740 KB

## Abstract Myocardial regeneration with stem‐cell transplantation is a possible treatment option to reverse deleterious effects that occur after myocardial infarction. Since little is known about stem cell survival after transplantation, developing techniques for “tracking” cells would be desirabl

Comparison of dysprosium DTPA BMA and su
Comparison of dysprosium DTPA BMA and superparamagnetic iron oxide particles as susceptibility contrast agents for perfusion imaging of regional cerebral ischemia in the rat
✍ Olav Haraldseth; Richard A. Jones; Tomm B. Müller; Anne K. Fahlvik; Audun N. Øks 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB

## Abstract The aim of the study was to compare the first‐passage profiles of dysprosium diethylenetriamine penta‐acetic acid bis(methylamide) (DTPA BMA) and the superparamagnetic iron oxide particles NSR 0430 in regions with severe and moderate cerebral ischemia. In seven rats subjected to middle